Recent Updates
Recently added Catalysts
TLX Positive Sentiment

AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®

Friday, April 25, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Telix Pharmaceuticals is set to present its urologic pipeline at the 2025 AUA Annual Meeting in Las Vegas. The company will showcase four abstracts on its theranostic programs and host two sessions featuring experts in urologic oncology. Key topics include imaging for prostate cancer and advancements in kidney cancer management.
Price reaction · baseline $19.4003 (2025-04-25T14:59:00.000Z) · hit during market hours · 3 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Telix is showcasing its innovative urologic pipeline at a major conference.
  • The company is presenting multiple abstracts on late-stage and commercial programs.
  • Engagement with key opinion leaders highlights Telix's commitment to advancing urologic oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

AUA25 : Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®

Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas, NV.
The Venetian Convention & Expo Center 201, Sands Avenue, 89169, Las Vegas, Nevada, United States
April 26 – 28, 2025 The full congress schedule can be viewed here
The congress will feature four abstract presentations on Telix’s late-stage and commercial theranostic programs. Presentations cover:
The Company will also present two thought leadership sessions at the Telix Product Theater, featuring key opinion leaders in urologic oncology – one on Illuccix® imaging for the staging of prostate cancer , and a second on the future of kidney cancer detection and management. Visit booth #1360 to discuss Telix’s extensive theranostic portfolio in urology targeting PSMA, CAIX and FAP across prostate, kidney and bladder cancers, its investigational pan-cancer programs, associated medical technologies, and opportunities for collaboration.
See below for full details
Weill Cornell Medicine
ProstACT Global: A Phase 3 study of TLX591 (177Lu-rosopatamab) plus standard of care vs. standard of care alone in patients with metastatic castration-resistant prostate cancer
Monday, April 28 | 1:00 PM – 1:08 PM (PDT Location: Hall C, The Square, Learning Lab
UCLA Department of Urology
Cost-effectiveness analysis of TLX250-CDx (89Zr-girentuximab) PET/CT to guide management of small renal masses
April 26 | 3:30 PM – 5:30 PM (PDT) Location: Cassanova 501
Indiana University
Can the sensitivity of Illuccix (68Ga-PSMA-11) PET/CT be enhanced with newer higher resolution PET/CT cameras?
Monday, April 28 | 1:00 PM – 3:00 PM (PDT) Location: Marco Polo 701
Indiana University
Pathology reported prostatectomy margin status does not predict the odds of PSMA-PET-detected fossa recurrence.
Tuesday, April 29 | 9:30 AM – 11:30 AM (PDT) Location: Cassanova 501
The University of Miami Health System
Illuccix® for 68Ga PSMA-11 imaging for the staging of prostate cancer
Monday, April 28 | 11:30 AM (PDT) Location: Telix AUA Product Theater, Science & Technology Hall Booth #2001
Vanderbilt University Medical Center
The future of kidney cancer detection and management
Sunday, April 27 | 2:30 PM (PDT) Location: Telix AUA Product Theater, Science & Technology Hall Booth #2001

Presenters

Frequently Asked Questions

What is Telix showcasing at AUA 2025?

Telix is showcasing its urologic pipeline, including theranostic programs and key presentations.

Where is the AUA 2025 meeting held?

The AUA 2025 meeting is held at The Venetian Convention & Expo Center in Las Vegas.

What topics will Telix present at the conference?

Telix will present on prostate cancer imaging and future kidney cancer management.

When will Telix's presentations take place?

Presentations are scheduled from April 26 to April 28, 2025.

ShareAdd on Google
Tags: TLX Viatris Investor Conferences Healthcare Telix AUA 2025 prostate cancer kidney cancer theranostics
Last updated: Apr 25, 2025

Biotech snapshot

Lead asset
131I-IPAPhase 1
Neoplastic Disease →

Catalyst track record

+13%
best trade around TLX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for TLX.

See every catalyst's timing & PoA →